Ionizing radiation therapy is one of the primary modalities for treating cancers. Ideally, the particle selected to deliver ionizing radiation for routine therapy should control the disease, cause minimal side effects, and be affordable. Two major properties for judging the utility of a particle, physical controllability and selective cell destruction, influence the decision for selection. The proton, at present, has the best combination of capabilities for routine radiation therapy. Heavier ions require further study to determine their role in patient treatment.
Introduction
Radiation therapy is one of the primary modalities for treating cancers. It is also a useful tool for treating many non-cancerous disease processes, particularly with the advent of highly conformable modalities such as heavy-chargedparticle irradiation. Cancer remains the greater problem: the American Cancer Society estimates that in 2007, 1,444,920 Americans will develop some form of cancer and 559,650 persons will die of their disease (1). The former figure is slightly higher than the estimate for the previous year; the latter estimate is slightly lower. Both figures continue trends that have been in place for at least a decade and a half. Progress in reducing the death rate is gratifying, but the scope of the problem remains enormous.
Radiation treatment of cancer should be evaluated in terms of patients' needs. The evaluation begins with an understanding of what cancers are.
Cancers arise from, and exist in, a milieu of normal cells and tissues. One might think of them as existing within a society. Rather than living as citizens within society, however, they are akin to sociopaths (Table I) . Normal cells are collaborative: they work together; they communicate. Cancer cells compete with the cells of their milieu and are committed, one may say, to their own survival at the expense of others and of the larger society. Normal cells are productive throughout their healthy lives; if diseased, they undergo apoptosis -programmed self-destruction or suicide that is built into the genetic code of the normal cell. The cancer cell's capacity for apoptosis is significantly reduced; it proceeds through almost unlimited multiplications regardless of its abnormality. Then, by mechanisms such as direct invasion, intracavitary extension, and the invasion of -and subsequent travel through -lymph and blood channels, cancer cells attack the host.
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Technology in Cancer Research & Treatment, Volume 6, Number 4 Supplement, August 2007 ful for 110 years; the selective capacity can be exploited by means such as dose fractionation to help promote survival of normal cells at the expense of cancer cells in the treatment volume. This selectivity is not absolute: sufficiently high radiation doses will damage any cell, normal or abnormal, beyond its ability to effect repair. Nonetheless, within appropriate dose limits, the parameter of selectivity can be used by the radiation oncologist to treat cancer patients.
It is the physician's knowledge of cancer and its dispersion patterns, combined with acknowledgement of the milieu in which cancers form and spread, that constitute the basis for treating the patient and managing the disease. Added to these are the radiation oncologist's knowledge of available tools, the most fundamental of which is the particle chosen to deliver ionizing radiation. This particle should have a combination of capabilities that permit the radiation oncologist to meet patients' needs as completely as possible.
Salient Factors to Consider in Matching Available Particles to Patients' Needs
Every patient treated with ionizing radiation has three essential needs: (i) to be treated with a modality that offers a high likelihood of controlling her or his disease; (ii) to be treated with a modality that reduces the likelihood of treatment-related morbidity as much as possible; and (iii) to receive affordable treatment. Particle selection is related to all three factors.
The ability to minimize normal-tissue injury may be the most important factor in particle selection, for if injuries to normal tissues are too severe or too extensive, treatment of the diseased volume and its probable extensions may be subject to unacceptable consequences. In some instances treatment should not be initiated, especially in presentations where highly radiosensitive normal structures are in close proximity to the diseased volume. Optimally, the patient should be treated with a particle that is inherently conformable; lacking this, the physician must devise suboptimal therapy plans that minimize normal-tissue exposure as much as possible.
Cancer control is the primary objective of oncologists. The ability of a radiation modality to effect control is related to the quantity and pattern of ionization events it delivers. One factor affecting this ability is dose: it is accepted that any form of radiation can control cancer if the total dose is high enough. If there were such a thing as an "ideal" beam ( Fig.  1 ), normal-tissue injury would be simpler to prevent. No such beam yet exists, however; radiation oncologists must approximate the ideal as nearly as possible and, for some treatment situations, must also consider the radiobiologic effectiveness (RBE) of the various particles available. RBE is related to linear energy transfer (LET), which can be thought of as the quantity of ionization events per volume of tissue traversed; the higher the LET, the greater the quantity of ionization events per volume of tissue irradiated, and the higher the RBE. The realities facing the radiation oncologist, however, such as the need to treat diseased tissues admixed with and in close proximity to normal tissues, make higher RBE a tool to employ judiciously. It is possible that higher-LET radiation, cautiously used, may be useful as a boost to treat solid tumor masses that are resistant to low-LET particles. Even this kind of usage must be attempted with great caution, however, when dealing with infiltrative cancer that is admixed with normal tissues.
Affordability is a concern for the obvious reason that tooexpensive radiotherapy modalities and facilities may not be used sufficiently to amortize their development and operating costs. Particles with superior characteristics for therapy must be employed, therefore, in ways that maximize the efficiency and precision with which they are delivered. Proton and other heavy-charged-particle treatment centers are much more expensive to develop than facilities employing electron linear accelerators for delivering X rays and electrons; planners of the former facilities must, therefore, incorporate technology and design considerations that permit the facility to operate uninterruptedly and with a high volume of patient throughput. In addition, the particle selected should permit economical operation; a proton facility, for example, costs much less No concern for colleagues Healthy to death Multiple abnormal genetic changes Figure 1: Crude representation of an "ideal" radiation beam for treating a patient with prostate cancer. Such a beam would enter the patient without depositing ionizing energy; deposit no energy en route to the target volume; and deposit all of its energy within the target, thus not irradiating tissues around or beyond the target.
to build than a facility employing heavier ions, and as such, its costs can be amortized sooner or with fewer patients, assuming the same level of operating efficiency in both. Differences in development and operating costs may require that fewer of the more-expensive facilities be built, and that their use be allocated to situations in which they offer unique advantages.
Several particles are available today for radiation therapy (Table II) (2-4). They can be subdivided grossly into forcecarrier particles and matter particles (Fig. 2) ; photons are the predominant type employed today, as has been the case since Roentgen's discovery of X rays. All available particles can be analyzed in terms of two salient factors that affect their utility for treatment: physical controllability and selective cell destruction.
Physical Controllability
Mass and charge affect the physician's ability to deliver a particle where desired. The greater the physician's ability to place particles physically into the desired treatment volume, and to spare normal tissues, the more likely it is that the full therapeutic dose can be delivered without interrupting treatment owing to side effects caused by excessive radiation exposure of normal tissues.
Photons (X-and gamma rays) have no charge, nor do neutrons. Electrons, negative pi-mesons, protons, and heavier charged particles do have a charge, making electronic control of these particles possible. Electronic control is only one aspect of physical controllability, however; for example, electrons can be guided electronically but, owing to their slight mass, scatter more diffusely than is desirable, as do photons, when they traverse tissue. Both photons and electrons produce ionization events, the former by virtually colliding with the electrons in tissue, the latter by repelling the like-charged particles as they come in close proximity, but both cause such scattering that physical control by electronic means is not possible (Fig. 3) . Mechanical means, such as beam-shaping devices, are needed to conform the beam to the treatment volume as it enters the patient. Once the beam enters the patient, the physician has no further control over it and must rely on the inherent characteristics of the particle being used.
Heavy charged particles are highly controllable owing to their charge and mass. Protons, for example, have more than 1800 times the mass of electrons. Their greater mass enables them to pass through tissue with less likelihood of scattering than is true of photons and electrons. Some scattering does occur with protons and heavier charged particles (progressively less as the mass of the particle increases) but for the most part, mass prevails and the particles follow an essentially straight path.
Protons and all heavy charged particles display Bragg peaks, another component that assists in physical controllability ( Fig. 4 ). This property, added to the reduced lateral scattering owing to mass, enables the physician to control the dose distribution in three dimensions within the patient; almost no radiation is deposited beyond the locus of the Bragg peak in tissue.
Physical controllability enables the physician to maximize precision, and thus helps to deliver the particles into the target. Heavy charged particles, at present, provide the best means of obtaining such controllability. 
Selective Cell Killing Attributes
Given that ionization events initiate the process that leads to cell injury, including DNA damage, the radiation oncologist's goal is to maximize ionization events in targeted cells and minimize such events in normal tissue. Minimizing normal-cell injury is an absolute must. Given that no "ideal" radiation beam (Fig. 1) exists, however, damage to normal cells always occurs. Given that radiation exposure of normal cells is unavoidable, it is desirable that the exposure be from low-LET particles. Protons, photons, and electrons all have this property (Table III) ; the latter two, however, have poor controllability.
Ions heavier than hydrogen ions comprise clusters of protons and neutrons. The density of ionization events associated with these heavy ions can be thought of, perhaps simplistically, as a function of the number of protons each ion contains (Fig. 5 ). Greater ionization density translates almost directly into higher LET (and RBE), which in turn translates into a higher probability of causing irreparable damage to cells. This is a highly desirable characteristic when irradiating a target containing only diseased cells, but becomes undesirable when diseased cells are infiltrating diffusely among normal cells. The clinician almost always is confronted with a situation wherein a mass of solid tumor is surrounded by a volume of diffusely infiltrating cells.
Selective cell destruction, which is helpful to the clinician in most presentations, is less likely to prevail if heavy ions are used. A high-LET particle may be desirable in selected instances. For example, following an initial course of low-LET radiation to the primary tumor and its regional spread, a high-LET particle may be used for boost therapy to the core solid tumor mass. A high-LET particle may also be useful in treating tumors known to be highly radioresistant.
Discussion
The optimum particle, like the "ideal" beam, is unlikely to be identified. The clinician who offers radiation therapy for a spectrum of patients faces the necessity to select a particle offering a combination of competencies that approach the ideal. Given the patient's salient needs -effective disease control, no or minimal radiation-related morbidity, and affordability -the particle coming closest to the ideal at the moment is, in my opinion, the proton. This is not to suggest that other particles have no place and should not be studied; quite the opposite is true, especially the heavier ions, which have a younger clinical history than protons, electrons, and photons. Future studies may identify situations wherein combinations of particles should be employed routinely in clinical practice, such as suggested above for protons and heavy ions. Investigations of all possibilities should be encouraged.
Several avenues of investigation are being followed at Loma Linda University Medical Center, where we have employed proton radiation treatment in a hospital-based therapy facility since 1990. We are interested in overcoming some limitations we face in spite of using a highly controllable, low-LET beam. For example, we are working with radiation sensitizers, in the hope that the subsequent dose required to destroy the cells would be less. We are exploring various radioprotectors for the normal surrounding tissues. We are exam- ining altered fractionation schemes, both hypofractionation and hyperfraction, as our investigations suggest that some malignant cells respond better to many small fractions, and others do better with fewer large ones. We are enhancing the precision and reproducibility of patient set-ups by employing a precision patient alignment system, a computerdriven, robotic system that also will enable us to increase patient throughput. We have for many years been working on an active beam delivery system, a fully electronic scanning beam that will increase the precision of dose delivery and enable treatment of patients requiring both very small fields and larger, more irregular fields.
All of these investigations build on the proton, which we selected for its controllability, selective cell-killing properties, and affordability. Controllability and selective cell killing are the most important features. Controllability enables us to grossly avoid normal tissues better than can be accomplished by any photon-based modality (Figs. 6, 7) . Selective cell killing is also essential because it offers normal cells an opportunity to recover when they are unavoidably irradiated at the microscopic level. The latter property is important because, in routine radiation therapy, normal cells are likely to be admixed with tumor cells. Affordability, abetted by efficiency in operation, makes it possible to offer the modality as a mainstream treatment. Protons are more expensive to develop and deliver than photons, but less so than heavier particles. With further development and economies of scale that should obtain as protons become more commonplace, the affordability of proton facilities likely will increase. The true cost of developing HZ-particle facilities, like their ultimate applications, remains a matter for study.
Tables 4 and 5 summarize the attributes of currently available particles for primary radiotherapy and for boost treatments. Much investigation is needed to determine the ultimate roles of all radiotherapeutic modalities. None, save perhaps photons, has likely reached its optimum application, and combinations of particle types, perhaps combined further with non-ionizing particles and molecules, may be the wave of the future. Cooperative multidisciplinary research programs are needed to help us approach optimal radiotherapeutic strategies to meet patients' needs.
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Low Controllability 6-Field IMRT X-Ray Figure 6 : Comparison of proton (left) and intensity-modulated radiation therapy (IMRT) photon plans for prostate cancer. In the proton plan, the volume of body receiving > 2 Gy of radiation is 2451 cm 3 ; in the IMRT plan, the corresponding volume is 6343 cm 3 , 2.59 times higher. Courtesy of Michael Moyers, Ph.D. (personal communication).
Figure 7:
Comparison of proton (left) and intensity-modulated radiation therapy (IMRT) photon plans for a tumor in the chest. In the proton plan, the volume of body receiving > 2 Gy of radiation is 1038 cm 3 ; in the IMRT plan, the corresponding volume is 2564 cm 3 , 2.74 times higher. Courtesy of Michael Moyers, Ph.D. (personal communication).
